-
Product Insights
Hemophilia A (Factor VIII Deficiency) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update
Hemophilia A (Factor VIII Deficiency) Clinical Trials Market Report Overview The Hemophilia A (Factor VIII Deficiency) clinical trial market research report provides an overview of the Hemophilia A clinical trials scenario. The report provides top-line data relating to the clinical trials on Hemophilia A. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Product Insights
Thalassemia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update
Thalassemia Clinical Trials Market Report Overview The Thalassemia clinical trial market research report provides an overview of the Thalassemia clinical trials scenario. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Market Report Overview Immune Thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and suppression of platelet production. This increases an affected individual’s susceptibility to bleeding. More specifically, the destruction and suppression of platelets are due to B cell (and sometimes CD8+ T cell) autoimmune reactions directed against circulating platelets and megakaryocytes. The Immune Thrombocytopenia marketed and pipeline drugs market includes an assessment of the disease epidemiology, leading...
-
Product Insights
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Report Overview The idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) clinical trial market research report provides an overview of the idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) clinical trials scenario. The report provides top-line data relating to the clinical trials on idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura). It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region,...
-
Product Insights
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness, and inability to think clearly. The renal...
-
Product Insights
Hemophilia B (Factor IX Deficiency) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The hemophilia B clinical trial market research report provides an overview of the hemophilia B clinical trials scenario. The report provides top-line data relating to the clinical trials on hemophilia B. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Sickle Cell Disease with Vaso-Occlusive Crisis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration, and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion, and surgery. The Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease with Vaso-Occlusive Crisis, complete with analysis by stage of development, drug target,...
-
Product Insights
Hypereosinophilic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out. The Hypereosinophilic Syndrome pipeline drugs market research report provides...
-
Product Insights
Aplastic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Its symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds or bleeding gums, prolonged bleeding from cuts, skin rash, dizziness, and headache. The Aplastic Anemia pipeline market research report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA),...
-
Product Insights
Fanconi Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less...
-
Product Insights
Febrile Neutropenia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Febrile Neutropenia clinical trial market research report provides an overview and top-line data relating to the clinical trials on Febrile Neutropenia. The report includes an overview of trials count and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of...
-
Product Insights
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness, and yellowish color to the skin (jaundice). The TTP pipeline drugs market research report outlays comprehensive information on the TTP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA),...
-
Product Insights
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain, and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion, and stem cell transplant. The Sickle Cell Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Its treatment includes replacing the defective clotting factor. The Hemophilia B pipeline market research report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Paroxysmal Nocturnal Hemoglobinuria include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache, and shortness of breath. Its treatment includes surgery, chemotherapy, and radiation therapy. The Paroxysmal Nocturnal Hemoglobinuria pipeline market research report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections, and dysuria. The Neutropenia pipeline market research report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Hemophilia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Hemophilia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hemophilia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report...
-
Product Insights
Myelofibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Myelofibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Hemophilia A (Factor VIII Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research...
-
Product Insights
Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hemorrhage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemorrhage, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report...